Brief Summary

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Approved for marketing
Mesothelioma

Drug: Pemetrexed

Drug: Cisplatin

Eligibility Criteria

Inclusion Criteria:

- Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery

- Prior chemotherapy for your disease is allowed

- Measurable lesion is not required

- Have a adequate performance status

- Sign an informed consent form

Exclusion Criteria:

- You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study

- You are excluded from this trial if you have received radiation within the previous 2 weeks

- You are excluded from this trial if you are a candidates for curative surgery

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Brazil
Egypt
Saudi Arabia
United States
Locations

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Basking Ridge, New Jersey,

Eli Lilly and Company
NCT Number
MeSH Terms
Mesothelioma
Pemetrexed